You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 62 No. 7, July 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (16)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Genetic Counseling/ Testing/ Therapy
 •Neurogenetics
 •Alert me on articles by topic

Spectrum of Mutations in Biopsy-Proven CADASIL

Implications for Diagnostic Strategies

Nils Peters, MD; Christian Opherk, MD; Tanja Bergmann; Mirna Castro, PhD; Jürgen Herzog, MD; Martin Dichgans, MD

Arch Neurol. 2005;62:1091-1094.

Background  Mutations in the NOTCH3 gene are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is an important cause of stroke in young adults. Mutations are typically located within epidermal growth factor–like repeat domains in the extracellular part of the Notch3 receptor. Identification of the mutation is critical for genetic counseling and testing of relatives at risk.

Objectives  To identify the spectrum of NOTCH3 mutations in CADASIL and to discuss the implications for diagnostic strategies.

Design  Screening for NOTCH3 mutations was performed in 125 unrelated German CADASIL patients with biopsy-proven disease by direct sequencing of exons coding for epidermal growth factor–like repeats. Results were compared with those of previously published studies.

Results  We detected 54 distinct mutations (117 missense mutations and 3 in-frame deletions) in 120 (96.0%) of the 125 patients. Of the mutations, 58.3% were located in exon 4 and 85.8% in exons 2 through 6. In 5 patients (4.0%), no mutation was identified.

Conclusions  Almost 90% of mutations could be detected within a few exons (exons 2-6). Thus, genetic testing should initially be focused on these exons, with some variation depending on the population in whom it is being performed. Yet, genetic testing for CADASIL is associated with a nameable proportion of false-negative results. Cases with a high index of clinical suspicion should be investigated by skin biopsy if genetic testing is negative.


Author Affiliations: Department of Neurology, Neurogenetics Laboratory, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The role of genetics in stroke
Francis et al.
Postgrad. Med. J. 2007;83:590-595.
ABSTRACT | FULL TEXT  

The archetypal R90C CADASIL-NOTCH3 mutation retains NOTCH3 function in vivo
Monet et al.
Hum Mol Genet 2007;16:982-992.
ABSTRACT | FULL TEXT  

Hereditary multi-infarct dementia of the Swedish type is a novel disorder different from NOTCH3 causing CADASIL
Low et al.
Brain 2007;130:357-367.
ABSTRACT | FULL TEXT  

Heritability of MRI Lesion Volume in CADASIL: Evidence for Genetic Modifiers
Opherk et al.
Stroke 2006;37:2684-2689.
ABSTRACT | FULL TEXT  

Advances in Vascular Cognitive Impairment 2005
Chui and Skoog
Stroke 2006;37:323-325.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.